454 related articles for article (PubMed ID: 9506679)
1. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
[TBL] [Abstract][Full Text] [Related]
2. Membranoproliferative glomerulonephritis type III: association of glomerular deposits with circulating nephritic factor-stabilized convertase.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Jul; 32(1):56-63. PubMed ID: 9669425
[TBL] [Abstract][Full Text] [Related]
3. Paramesangial glomerular deposits in membranoproliferative glomerulonephritis type II correlate with hypocomplementemia.
West CD; McAdams AJ
Am J Kidney Dis; 1995 Jun; 25(6):853-61. PubMed ID: 7771481
[TBL] [Abstract][Full Text] [Related]
4. The alternative pathway C3 convertase and glomerular deposits.
West CD; McAdams AJ
Pediatr Nephrol; 1999 Jun; 13(5):448-53. PubMed ID: 10412868
[TBL] [Abstract][Full Text] [Related]
5. Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2.
West CD; Witte DP; McAdams AJ
Am J Kidney Dis; 2001 Jun; 37(6):1120-30. PubMed ID: 11382679
[TBL] [Abstract][Full Text] [Related]
6. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III.
Varade WS; Forristal J; West CD
Am J Kidney Dis; 1990 Sep; 16(3):196-206. PubMed ID: 2205097
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
Strife CF; Prada AL; Clardy CW; Jackson E; Forristal J
J Pediatr; 1990 May; 116(5):S98-102. PubMed ID: 2329415
[TBL] [Abstract][Full Text] [Related]
10. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
[TBL] [Abstract][Full Text] [Related]
11. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
12. A hemolytic method for the measurement of nephritic factor.
West CD
J Immunol Methods; 2008 Jun; 335(1-2):1-7. PubMed ID: 18410942
[TBL] [Abstract][Full Text] [Related]
13. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
14. Nephritic factors predispose to chronic glomerulonephritis.
West CD
Am J Kidney Dis; 1994 Dec; 24(6):956-63. PubMed ID: 7985676
[TBL] [Abstract][Full Text] [Related]
15. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
16. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
17. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
18. Discordant renal histopathologic findings and complement profiles in membranoproliferative glomerulonephritis type III.
Meyers KE; Strife CF; Witzleben C; Kaplan BS
Am J Kidney Dis; 1996 Dec; 28(6):804-10. PubMed ID: 8957031
[TBL] [Abstract][Full Text] [Related]
19. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
20. [Ultrastructural study on membranoproliferative glomerulonephritis with special reference to subepithelial deposits].
Sato H
Nihon Jinzo Gakkai Shi; 1990 Sep; 32(9):973-83. PubMed ID: 2263028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
